Melkart Duo

Metformin Hydrochloride and Vildagliptin, the active ingredients in Melkart Duo, are a Biguanide and DPP‑4 inhibitor presented as an oral tablet for oral use. They are indicated for the management of type 2 diabetes mellitus in adult patients, helping to control blood glucose levels.

GNH USA supplies Melkart Duo as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Melkart Duo combines metformin and vildagliptin to target hyperglycaemia in type 2 diabetes mellitus.

- Type 2 diabetes mellitus: improves glycaemic control when used with diet and exercise. - Inadequate control on metformin alone: provides additional DPP‑4 inhibition to achieve target glucose levels. - Adjunct therapy: can be added to other antidiabetic agents as part of a comprehensive treatment regimen.

Common Side Effects: - Gastrointestinal upset: nausea, abdominal discomfort, or diarrhoea. - Headache: mild to moderate intensity. - Upper respiratory tract infection symptoms. - Dizziness or light‑headedness. - Mild hypoglycaemia when combined with other glucose‑lowering agents.

Serious or Rare Side Effects: - Lactic acidosis: a rare but life‑threatening metabolic complication. - Pancreatitis: severe abdominal pain with elevated enzymes. - Severe allergic reactions: rash, angio‑edema, or anaphylaxis. - Hepatic dysfunction: jaundice or abnormal liver tests. - Persistent vomiting leading to dehydration.

Before initiating therapy, consider the following precautions: - Renal function: assess eGFR; avoid in severe renal impairment. - Hepatic disease: monitor liver enzymes and avoid in severe hepatic dysfunction. - Lactic acidosis risk: discontinue if patient experiences unexplained acidosis symptoms. - Vitamin B12 monitoring: long‑term metformin use may reduce B12 levels. - Pregnancy and lactation: safety not established; weigh benefits against potential risks. - Store at ambient temperature: keep below 25 °C, protect from moisture and keep in original packaging.

Metformin and vildagliptin may interact with several medicines.

Major Interactions (Avoid): - Iodinated contrast media: can precipitate acute renal failure and increase metformin accumulation. - Cimetidine: may raise metformin plasma concentrations, increasing risk of lactic acidosis.

Moderate Interactions (Monitor Closely): - Diuretics: may affect renal clearance of metformin. - ACE inhibitors or ARBs: monitor renal function and potassium levels. - Alcohol: potentiates risk of lactic acidosis. - Sulfonylureas or insulin: increased risk of hypoglycaemia. - Strong CYP3A4 inhibitors: may elevate vildagliptin levels.